Klotho Neurosciences Reaffirms Compliance with NASDAQ Listing Standards
Klotho Neurosciences, Inc. Restores NASDAQ Compliance
In a recent announcement, Klotho Neurosciences, Inc. (NASDAQ: KLTO) has officially confirmed its compliance with NASDAQ listing requirements. This comes after the company received a notification letter from NASDAQ, indicating it had met both the minimum closing bid price and stockholder equity standards, crucial for maintaining its listing on the stock exchange.
The company, dedicated to pioneering gene and cell therapies aimed at tackling neurodegenerative and age-related conditions, has achieved compliance with the minimum bid price of $1.00 and stockholders' equity of at least $2.5 million. This crucial achievement ensures Klotho’s continued presence in the competitive biotechnology sector.
After a period of scrutiny which began when Klotho was initially at risk of delisting due to equity deficiencies, Klotho has worked diligently to meet the necessary financial benchmarks. This not only affirms the company's financial stability but also reflects the ongoing efforts placed on advancing its innovative treatment options, particularly those that utilize the
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.